BG Medicine is a life sciences company focused on the discovery, development and commercialization of novel molecular diagnostics based on biomarkers to improve patient outcomes and contain healthcare costs. BG Medicine discovers biomarkers and is developing its diagnostic product candidates using its proprietary, versatile, and scalable technology platform which integrates and automates the precise measurement, analysis, characterization and interpretation of proteins, and metabolites collected from bodily fluids. For more information about BG Medicine, see www.bg-medicine.com.

Corgenix manufactures the BG Medicine Galectin-3 ELISA product, an in-vitro diagnostic product used in conjunction with clinical evaluation as an aid in assessing the prognosis of patients diagnosed with chronic heart failure.

Randox is an international diagnostics company, headquartered in the UK. Currently the twenty-third largest diagnostics company in the world, Randox develops, manufactures and markets clinical diagnostic products worldwide. Core products are: Biochip Array Technology; clinical chemistry analyzers and reagents; quality controls and external quality assurance programs; environmental diagnostics; recombinant proteins and antibodies. More information is available at www.randox.com.

Corgenix and Randox are collaborating on the application of some of the Corgenix products to Randox delivery platforms.